LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR (NASDAQ: LNSR) announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members, total 875 shares with an exercise price of $10.65 per share, matching the closing price on February 3, 2025.
The options will vest 25% on the one-year anniversary of the grant date, followed by thirty-six monthly installments, contingent on continued employment. The options have a 10-year term and are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan and stock option agreements.
LENSAR (NASDAQ: LNSR) ha annunciato l'assegnazione di opzioni su azioni a due nuovi dipendenti non esecutivi come incentivo all'assunzione. Le assegnazioni, approvate dai membri indipendenti del consiglio, ammontano a 875 azioni con un prezzo di esercizio di $10,65 per azione, corrispondente al prezzo di chiusura del 3 febbraio 2025.
Le opzioni verranno acquisite al 25% all'anniversario di un anno dalla data di concessione, seguite da trentasei rate mensili, a condizione di un impiego continuato. Le opzioni hanno un termine di 10 anni e sono regolate dal Piano di Incentivazione per l'Occupazione del 2024 di LENSAR e dagli accordi sulle opzioni su azioni.
LENSAR (NASDAQ: LNSR) anunció la concesión de opciones sobre acciones a dos nuevos empleados no ejecutivos como incentivos de empleo. Las concesiones, aprobadas por miembros independientes de la junta, totalizan 875 acciones con un precio de ejercicio de $10.65 por acción, igualando el precio de cierre del 3 de febrero de 2025.
Las opciones se otorgarán en un 25% en el primer aniversario de la fecha de concesión, seguidas de treinta y seis cuotas mensuales, condicionadas a la continuidad del empleo. Las opciones tienen un plazo de 10 años y están regidas por el Plan de Incentivos de Empleo de 2024 de LENSAR y los acuerdos de opciones sobre acciones.
LENSAR (NASDAQ: LNSR)는 두 명의 새로 고용된 비상무 직원에게 고용 유인을 제공하기 위해 주식 옵션을 부여한다고 발표했습니다. 독립 이사들에 의해 승인된 이 부여는 총 875주로, 행사 가격은 $10.65로, 2025년 2월 3일 종가와 일치합니다.
옵션은 부여일의 1주년 기념일에 25%가 확정되며, 이후 36개월 동안 월별로 지급됩니다. 옵션은 10년 기한을 가지며, LENSAR의 2024년 고용 유인 인센티브 수여 계획 및 주식 옵션 계약에 따라 규제됩니다.
LENSAR (NASDAQ: LNSR) a annoncé l'octroi d'options sur actions à deux nouveaux employés non exécutifs en tant qu'incitations à l'embauche. Les octrois, approuvés par des membres indépendants du conseil d'administration, totalisent 875 actions avec un prix d'exercice de 10,65 $ par action, correspondant au prix de clôture du 3 février 2025.
Les options seront acquises à 25 % à l'anniversaire d'un an de la date d'octroi, suivies de trente-six versements mensuels, sous réserve d'une poursuite de l'emploi. Les options ont une durée de 10 ans et sont régies par le Plan d'Incentive à l'Emploi 2024 de LENSAR et par les contrats d'options sur actions.
LENSAR (NASDAQ: LNSR) gab die Vergabe von Aktienoptionen an zwei neu eingestellte nicht-executive Mitarbeiter als Anreiz zur Einstellung bekannt. Die von unabhängigen Vorstandsmitgliedern genehmigten Zuwendungen belaufen sich auf insgesamt 875 Aktien zu einem Ausübungspreis von $10,65 pro Aktie, was dem Schlusskurs am 3. Februar 2025 entspricht.
Die Optionen werden zu 25 % am ersten Jahrestag des Vergabedatums fällig, gefolgt von sechsunddreißig monatlichen Raten, die von einer fortgesetzten Anstellung abhängen. Die Optionen haben eine Laufzeit von 10 Jahren und unterliegen dem Anreizplan für Beschäftigungsanreize 2024 von LENSAR und den Aktienoptionsvereinbarungen.
- None.
- None.
ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of February 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com / cradinovic@burnsmc.com |
FAQ
What is the exercise price of LENSAR's (LNSR) new stock options granted on February 3, 2025?
How many shares were included in LENSAR's (LNSR) February 2025 inducement grants?
What is the vesting schedule for LENSAR's (LNSR) February 2025 inducement stock options?
What is the term length of LENSAR's (LNSR) February 2025 inducement stock options?
